Inadequate use of preventive strategies in patients receiving NSAIDs

Clinical Drug Investigation

Volumn 25, Issue 4, 2005, Pages 265-270

  Francetic, I ^a   Bilusic, M ^a   Macolic Sarinic, V ^a   Huic, M ^a   Mercep, I ^a   Makar Ausperger, K ^a   Erdeljic, V ^a   Mimica, S ^b   Baotic, I ^c   Simic, P ^a  

^a KBC Zagreb   (Croatia)

^b KBC RIJEKA   (Croatia)

^c Institute Vuk Vrhovac Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CORTICOSTEROID; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROATIA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH PROTECTION;

EID: 17844383952     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525040-00006     Document Type: Article

References (30)

1. Paakkari H. Epidemiological and financial aspects of the use of non-steroidal anti-inflammatory analgesics. Pharmacol Toxicol 1994: 75 Suppl. 2: 56-9
2. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl 1989; 163: 3-8
3. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004; 364: 639-40
4. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74
5. Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des 2004; 10: 589-601
6. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84
7. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81
8. Ivey KJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage: actions of therapeutic agents. Am J Med 1988; 84 Suppl. 2A: 41-8
9. Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432-4
10. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22
11. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99
12. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology 2001; 120: 594-606
13. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037-46
14. Schoenfeld P, Kimmey MB, Scheiman J, et al. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications - guidelines for prevention and treatment. Aliment Pharmacol Ther 1999; 13: 1273-85
15. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991; 32: 252-5
16. Ehsanullah RS, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal antiinflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017-21
17. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277-80
18. Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69-75
19. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Orneprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-26
20. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727-34
21. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003; 115: 715-20
22. Parente F, Cucino C, Gallus S, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 2003; 17: 1503-6
23. Sturkenboom MCJM, Burke TA, Dieleman JP, et al. Under-utilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42 Suppl. 3: 23-31
24. Carvajal A, Arias LHM, Vega E. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs: a drug utilization study. Eur J Clin Pharmacol 2004; 60: 439-44
25. Clinard F, Bardou M, Sgro C, et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. Eur J Clin Pharmacol 2001; 57: 737-43
26. Chan FKL, Sung JY, Chung SCS, et al. Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9
27. Konturek JW, Fuchs W, Elbert J, et al. The prevalence of Helicobacter pylori infection in long-term users of nonsteroidal antiinflammatory drugs [abstract]. Gastroenterology 1998; 114: G0762
28. Hawkey CJ, Tullassay Z, Szcepanski L, et al. Failure of Helicobacter pylori eradication to influence site-specific relapse in high risk NSAID users: results of a large six month double blind randomised controlled clinical trial [abstract]. Gastroenterology 1998; 114: G0594
29. Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6
30. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296